Langerhans cell histiocytosis (LCH) is a rare disorder in adults, presenting as single organ or multisystem disease, with pulmonary disease occurring more frequently in isolation. 1 Failure of chemotherapy is reported in 20% of cases with multisystem LCH with overall survival of only 20%. 2, 3 Reports of myeloablative allogeneic stem cell transplantation in isolated cases of refractory LCH in children are described. 4, 5 A high transplant-related mortality, particularly in the presence of pre-existing end-organ damage, limits its use.
A recent report of nine children with poor-risk LCH treated with reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation (RIC allo-HSCT) showed encouraging results with 7/9 cases having no disease progression and alive at a median follow-up of 390 days with only one case showing non-engraftment. 6 The benefit of alemtuzumab (Campath-1H) incorporated into the pre-transplant conditioning is twofold. A significant reduction in the incidence of GvHD is well described and in addition, Jordan et al. 7 report the binding of alemtuzumab to pathological Langerhans cells (LCs) in LCH but not to normal LCs, suggesting a further target for therapy.
We report the worlds' first adult case of multisystem LCH with pulmonary involvement and thrombocytopenia with absent radii (TAR) successfully treated with RIC allo-HSCT. A 21-year-old woman presented to the orthopaedic specialists with a fracture of the left pelvis. Magnetic resonance imaging and radionuclide bone scans revealed multiple lytic lesions in the pelvis, left femur, tibia and right glenoid. The cells expressed S100 and CD1a, confirming a diagnosis of bone LCH. Her past medical history included a diagnosis, at birth, of TAR, with the platelet count stabilising at 30-40 Â 10 9 /l during adolescence with few bleeding complications.
A pulmonary computed tomography (CT) performed because of the increased dyspnoea (functional grade III) revealed characteristic features of pulmonary LCH, comprising numerous thin-walled cysts with relative sparing of the lower zones, and many of the cysts had bizarre outlines ( Figure 1 ). However, in addition to the typical parenchymal changes, the possibility of pulmonary arterial hypertension (PAH) was raised owing to the increased ratio of the transverse diameter of the main pulmonary trunk to the ascending aorta (27.2/25.6 mm) and prominence of pulmonary arterial branches in the periphery of both lungs 8 ( Figure 2a and b) . Echocardiography showed no elevation of right heart pressure, therefore no cardiac catheterisation was performed. Pulmonary function tests (PFTs) demonstrated an obstructive defect (% predicted FEV 1 and FEV 1 / FVC ratios 49 and 63% respectively), with a significant reduction of gas transfer (% predicted DLCO corrected for Hb 40%). She gave a six-pack-year smoking history. Bone marrow aspirate was reactive, with 1% abnormal histiocytes, normal cytogenetics and Fanconi anaemia screen negative.
A RIC sibling allo-HSCT was performed because of the extensive nature of the disease, incorporating fludarabine (150 mg/m 2 ), busulphan (8 mg/kg) and Campath-1H (100 mg) as pre-transplant conditioning. The case described underwent RIC allo-HSCT as first-line therapy because of concerns over a higher risk of bleeding complications due to the pre-existing thrombocytopenia (TAR). Full donor engraftment was achieved on day þ 28; however at 6 months post transplant, mixed chimerism was identified on the CD3 þ cell fraction (46% donor) following which one infusion of donor leucocytes (5 Â 10 5 /kg CD3) was Ventilation-perfusion scintigraphy was negative. There was therefore no additional evidence in favour of pulmonary hypertension, and cardiac catheterisation was consequently not performed.
Despite no intervention, on continued follow-up over the subsequent year, a reduction in breathlessness with significant improvement in exercise tolerance and PFTs (DLCO of 79% predicted, FEV 1 80% predicted and FEV 1 / VC 69.3%) compared to pre-transplant was demonstrated. At 3 years post transplant, stable donor cell engraftment, normalisation of platelet count, no evidence of disease progression and no GvHD was reported.
Pulmonary involvement of LCH predominantly occurs in adults, presumably because of the strong relationship to cigarette smoking. 9 Reduced carbon monoxide diffusing capacity, low FEV 1 to FVC ratio and high residual volume negatively predict outcome in pulmonary LCH. 10 Pulmonary hypertension is a recognised but rare complication of pulmonary LCH, and the pathophysiology is poorly understood. 1 The case described is of particular interest, as despite impaired respiratory function pre-transplant, evidence of improvement in lung function on both spirometry and TLCO together with improvement in respiratory symptoms was documented on follow-up. Improvement is presumed to be in part due to the graft-versus-LCH effect following transplantation, along with the potential anti-LCH effect of alemtuzumab.
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation is well tolerated with low toxicity despite the presence of comorbid factors. Further studies are however needed in both adults and children to explore the precise role of RIC allo-HSCT in multisystem LCH. 
